MenB

Neisseria meningitidis (meningococcus) is a bacterium which causes meningitis and septicaemia.

Healthcare systems worldwide are dealing with increasing number of patients with impaired immune response due to several factors: HIV has become chronic disease due to advances in diagnostics and treatment, many patients take immunosuppressive medications to control inflammatory or autoimmune conditions. Also, chemotherapy for oncological diseases involves weakening of the immune system. These patients are often at increased risk of infections, some of which may be preventable by vaccination. However, immune response and protection acquired by vaccination may be impaired on these patients.

At SGVI, we are interested in studying the immune response to vaccinations in groups of immunocompromised patients, especially in People Living with HIV (PLWH). We have several on-going studies focusing on vaccine immunogenicity in immunocompromised patients at SGVI:

Current studies:

  • Propositive:

This is a phase IV, open label, interventional clinical trial sponsored by SGUL and funded by GSK to study safety and immunogenicity of two meningitis vaccines: MenACWY (Menveo®) and 4CMenB (Bexsero®) in adult patients with HIV infection.

  • Propositive Follow-up:

The second phase study after Propositive, sponsored by SGUL and funded by GSK, investigating long-term immunogenicity of MenACWY (Menveo®) and 4CMenB (Bexsero®) in the cohort of adult patients with HIV infection recruited to the Propositive study.

  • COVID-19 vaccines and HIV (David to fill in)

Future studies:

Project Team

Paediatric Clinical Research Fellow

Natalina Sutton

Paediatric Clinical Research Fellow

Zsofia Danos

Director

Paul Heath

Project Manager

Polly Fox

Paediatric Clinical Research Fellow

Natalina Sutton

Natalina is currently a Clinical Research Fellow at St George’s Paediatric Infectious Diseases Research Group, working on COVID-19 and MenACWY vaccine studies. She has over a decades experience in child health in global settings. She has applied 6 years of experience as a foundation doctor and paediatric trainee to global public health work including, participation in mobile clinics to ensure access to healthcare for remote populations in Belize, and development of health promotion projects in Ecuador and Mexico. Natalina has a MSc in Public Health from the London School of Hygiene and Tropical Medicine and has carried out research projects on predicting IVIG resistance in Kawasaki Disease and prevention of childhood obesity in preschool children.

Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove C, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jamal A, Jeanes C, Kalra PA, Kyriakidou C, McAuley DF, Meyrick A, Minassian AM, Minton J, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, San Francisco Ramos A, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J, Viljoen ME, Albert G, Cho I, Dubovsky F, Glenn G, Rivers J, Robertson A, Smith K, Toback S; 2019nCoV-302 Study Group. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med. 2021 Jun 30

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O’Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Erratum in: Lancet. 2021 Jan 9;397(10269):98.
Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJA, Emary KRW, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AVA, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 Mar 6;397(10277):881-891.

Davies S, Sutton N, Blackstock S, Gormley S, Hoggart CJ, Levin M, Herberg JA. Predicting IVIG resistance in UK Kawasaki disease. Arch Dis Child. 2015 Apr;100(4):366-8.

Paediatric Clinical Research Fellow

Zsofia Danos

Zsofia has been working in clinical paediatrics since 2014 and finished Paediatric training in November 2020. Zsofia started working for the paediatric infectious disease research group in September 2020. Her role as a clinical research fellow (currently mainly involved in the COVID-19 vaccine trials) includes recruitment and consenting of participants, reviewing medical history, vaccinating, conducting symptomatic reviews and covering on-call duties. Zsofia also works on the cChips CMV study and looking forward to be involved in other paediatric trials as well.

 

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

A Folyovich, I Vastagh, A Kéri, A Majoros, KL Kovács, A Ajtay, Zs Laki, B Gunda, K Erdei, L Lenti, Zs Dános, D Bereczki  Living standard is related to microregional differences in stroke characteristics in Central Europe: the Budapest Districts 8-12 Project  Int J Public Health  DOI 10.1007/s00038-015-0674-y  2015

D. Bereczki, A. Ajtay, A. Majoros, Z. Dános, L. Lenti, K. Erdei, L.K. Kovács, B. Gunda, Z. Laki, A. Kéri, I, Vastagh, A. Folyovich  Gender difference in the living standard on 3-year stroke fatality: the Budapest District 8-12 project.

Director

Paul Heath

Email:pheath@sgul.ac.uk

Secretary Phone:020 8725 3262

Project Manager

Polly Fox

I joined the PIDRG Team in September 2019 as a Project Officer working on a range of studies in RSV, fungal infections, AMR and vaccines. I’m now one of the Project Managers helping to deliver the COVID-19 Vaccine Trials we are running at St George’s as well as other Urgent Public Health studies such as a serological survey in children and young adults. I have also recently started an MSc Clinical Trials with LSHTM part-time to further my career development in trial coordination.

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial